

Freedom of Information Request	FOI 22-186	12 <sup>th</sup> May 2022
Freedom of information Request	LO1 55-100	IZ" May ZUZZ

I am analysing the treatment of dermatological conditions in the UK.

Could you please answer the following questions.

- Q1. How many patients were treated in last 4 months by the Dermatology department with each of the following:
  - Abrocitinib
  - Acitretin
  - Alitretinoin
  - Azathioprine
  - Baricitinib
  - Ciclosporin
  - Dupilumab
  - Methotrexate
  - Mycophenolate mofetil
  - Pimecrolimus
  - Tacrolimus ointment
  - Tralokinumab
  - Upadacitinib

Please find below the quantities dispensed in the Health Boards pharmacy for dermatology only. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

	Quantity
DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack	14
DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	9
DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Pen 2 Pre-Filled Pen Pack	118
DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	121
METHOTREXATE (METHOFILL) 20 mg in 0.4mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4
METHOTREXATE (METOJECT) 10 mg in 0.2mL Pre-Filled Pen 1 Pre-Filled Pen Pack	2
METHOTREXATE (METOJECT) 12.5 mg in 0.25mL Pre-Filled Pen 1 Pre-Filled Pen Pack	1
METHOTREXATE (METOJECT) 15 mg in 0.3mL Pre-Filled Pen 1 Pre-Filled Pen Pack	2
METHOTREXATE (METOJECT) 17.5 mg in 0.35mL Pre-Filled Pen 1 Pre-Filled Pen Pack	2

Q2. Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)? The Health Board does not record this information centrally and would have to review every patient record to determine this. Therefore, in order to

comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

Q3. How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic Dermatitis ONLY? Please refer to Q2.